p increased by 1.8%-points to Novo Nordisk ® Diabetes value market leadership expansion driven by the GLP-1 franchise Diabetes care sales grew by 14% with global value market share increase driven by GLP-1 market share gains in both IO and NAO GLP-1 value market share has increased by 2.2%-points in the last 12 months, driven by: • Ozempic ® launches and uptake in 75 countries • Rybelsus ® uptake in North America Operations and launches in International Operations • Global GLP-1 volume growth of ~50% • GLP-1 is only ~5% of total diabetes prescriptions
Download PDF file